Drozitumab Biosimilar uses the same protein sequences as the therapeutic antibody drozitumab.nnDrozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.nnAlthough drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.
应用类型
Flow cytometry, animal model study
免疫原
Human TRAIL
来源宿主
CHO cells
反应性
Human
保存建议
Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
其他
Tumour Necrosis Factor Related Apoptosis-inducing Ligand
